Edaravone Dexborneol for Blood-Brain Barrier Repair in Acute Anterior Circulation Stroke
A Multicenter Randomized Controlled Trial Study of the Effect of Edaravone and Dexcamphan on the Repair of Blood-brain Barrier Injury in Acute Infarction of Anterior Circulation
This multicenter randomized controlled trial evaluates the effect of edaravone dexborneol on blood-brain barrier repair in patients with acute anterior circulation large artery atherosclerotic ischemic stroke within 48 hours of onset.
Patients are randomized 1:1 to receive either edaravone dexborneol (30mg/7.5mg BID IV) or edaravone (30mg BID IV) for 9±2 days, in addition to standard stroke treatment. The primary outcome is the change in blood-brain barrier permeability (Ktrans) measured by DCE-MRI. Secondary outcomes include neurological function scores, serum biomarkers, and safety events.
연구 개요
연구 유형
등록 (추정된)
단계
- 4단계
연락처 및 위치
연구 연락처
- 이름: Qinjian Sun Qinjian
- 전화번호: +86 15168885366
- 이메일: sqj1210@163.com
연구 장소
-
-
Shandong
-
Jinan, Shandong, 중국, 250021
- 모병
- Shandong Provincial Hospital Affiliated to Shandong First Medical University
-
연락하다:
- Qinjian Sun Qinjian, Professor
- 전화번호: +86 15168885366
- 이메일: sqj1210@163.com
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Acute anterior circulation ischemic stroke within 48 hours of onset;
- Age 35-80 years;
- NIHSS score 4-24;
- Pre-stroke mRS score ≤1;
- Signed informed consent.
Exclusion Criteria:
- Lacunar infarction or multiple punctate infarcts;
- Intracranial hemorrhage;
- Moyamoya disease, vasculitis, or other immune-related infarcts;
- Combined tumor, intracranial infection, epilepsy, or severe systemic disease;
- History of non-lacunar ischemic stroke within 6 months;
- Severe liver or kidney dysfunction;
- MRI contraindications;
- Participating in other clinical trials.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
활성 비교기: Control Group
Participants receive edaravone 30mg BID intravenous drip for 9±2 days, plus standard stroke treatment. |
Edaravone 30 mg administered by intravenous drip twice daily (BID) for 9±2 days, in addition to standard guideline-based treatment for acute ischemic stroke.
다른 이름들:
|
|
실험적: Intervention Group
Participants receive edaravone dexborneol 30mg/7.5mg BID intravenous drip for 9±2 days, plus standard stroke treatment. |
Edaravone dexborneol (30 mg/7.5 mg) administered by intravenous drip twice daily (BID) for 9±2 days, in addition to standard guideline-based treatment for acute ischemic stroke.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change in Ktrans (blood-brain barrier permeability) measured by DCE-MRI
기간: From baseline (24-48 hours after stroke onset) to day 9±2 after treatment
|
Change in the volume transfer constant (Ktrans) in the infarct region, quantifying the degree of blood-brain barrier repair from baseline (within 24-48 hours after onset) to day 9±2 after treatment, assessed by dynamic contrast-enhanced MRI (DCE-MRI). |
From baseline (24-48 hours after stroke onset) to day 9±2 after treatment
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change in serum Occludin level
기간: Baseline to day 9±2 post-treatment
|
Change in serum Occludin level measured by Simoa technology. Unit: pg/mL. |
Baseline to day 9±2 post-treatment
|
|
Change in serum Fibronectin level
기간: Baseline to day 9±2 post-treatment
|
Change in serum Fibronectin level measured by Simoa technology. Unit: ng/mL. |
Baseline to day 9±2 post-treatment
|
|
Change in serum MMP-9 level
기간: Baseline to day 9±2 post-treatment
|
Change in serum Matrix Metalloproteinase-9 (MMP-9) level measured by Simoa technology. Unit: ng/mL. |
Baseline to day 9±2 post-treatment
|
|
Change in serum UCHL1 level
기간: Baseline to day 9±2 post-treatment
|
Change in serum Ubiquitin C-terminal Hydrolase L1 (UCHL1) level measured by Simoa technology. Unit: pg/mL. |
Baseline to day 9±2 post-treatment
|
|
Change in serum NOS level
기간: Baseline to day 9±2 post-treatment
|
Change in serum Nitric Oxide Synthase (NOS) level measured by Simoa technology. Unit: assay-specific unit. |
Baseline to day 9±2 post-treatment
|
|
Change in serum NSE level
기간: Baseline to day 9±2 post-treatment
|
Change in serum Neuron-Specific Enolase (NSE) level measured by Simoa technology. Unit: ng/mL. |
Baseline to day 9±2 post-treatment
|
|
Change in serum GFAP level
기간: Baseline to day 9±2 post-treatment
|
Change in serum Glial Fibrillary Acidic Protein (GFAP) level measured by Simoa technology. Unit: pg/mL. |
Baseline to day 9±2 post-treatment
|
|
Change in serum EAA level
기간: Baseline to day 9±2 post-treatment
|
Change in serum Excitatory Amino Acids (EAA) level measured by Simoa technology. Unit: µmol/L or assay-defined unit. |
Baseline to day 9±2 post-treatment
|
|
NIHSS score at day 9±2
기간: Day 9±2 after treatment
|
National Institutes of Health Stroke Scale (NIHSS) score. Higher scores indicate worse neurological deficit (Range: 0-42). |
Day 9±2 after treatment
|
|
mRS score at day 9±2
기간: Day 9±2 after treatment
|
modified Rankin Scale (mRS) score. Higher scores indicate worse functional outcome (Range: 0-6). |
Day 9±2 after treatment
|
|
MMSE score at day 9±2
기간: Day 9±2 after treatment
|
Mini-Mental State Examination (MMSE) score. Higher scores indicate better cognitive function (Range: 0-30). |
Day 9±2 after treatment
|
|
MoCA score at day 9±2
기간: Day 9±2 after treatment
|
Montreal Cognitive Assessment (MoCA) score. Higher scores indicate better cognitive function (Range: 0-30). |
Day 9±2 after treatment
|
|
NIHSS score at day 90±7
기간: Day 90±7 after treatment
|
National Institutes of Health Stroke Scale (NIHSS) score. Higher scores indicate worse neurological deficit (Range: 0-42). |
Day 90±7 after treatment
|
|
mRS score at day 90±7
기간: Day 90±7 after treatment
|
modified Rankin Scale (mRS) score. Higher scores indicate worse functional outcome (Range: 0-6). |
Day 90±7 after treatment
|
|
MMSE score at day 90±7
기간: Day 90±7 after treatment
|
Mini-Mental State Examination (MMSE) score. Higher scores indicate better cognitive function (Range: 0-30). |
Day 90±7 after treatment
|
|
MoCA score at day 90±7
기간: Day 90±7 after treatment
|
Montreal Cognitive Assessment (MoCA) score. Higher scores indicate better cognitive function (Range: 0-30). |
Day 90±7 after treatment
|
|
Hemorrhagic transformation
기간: From randomization to 90 days
|
Incidence of new cerebrovascular events during the study period. |
From randomization to 90 days
|
|
New cerebrovascular events during the study
기간: From randomization to day 90±7
|
Incidence of new cerebrovascular events (including new ischemic stroke, transient ischemic attack, or other cerebrovascular events) in enrolled patients during the study period. |
From randomization to day 90±7
|
|
Death during the study
기간: From randomization to day 90±7
|
All-cause mortality in enrolled patients during the study period. |
From randomization to day 90±7
|
|
Other adverse events during the study
기간: From randomization to day 90±7
|
Incidence of other adverse events (AEs) in enrolled patients during the study period, excluding serious adverse events, hemorrhagic transformation, new cerebrovascular events, and death. Adverse events will be coded using MedDRA and summarized by system organ class and preferred term. |
From randomization to day 90±7
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- SWYX:NO.2021-1020
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .